Creso Pharma Limited
COPHF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 11.10 | 22.19 | 73.87 |
| FCF Yield | 0.00% | -0.39% | -0.05% | -0.02% |
| EV / EBITDA | -0.36 | -453.50 | -1,791.30 | -2,805.87 |
| Quality | ||||
| ROIC | -298.47% | -67.56% | -107.93% | -121.59% |
| Gross Margin | 12.34% | 3.30% | -6.44% | -158.61% |
| Cash Conversion Ratio | – | 0.94 | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 44.91% | 52.55% | 19.69% | 61.77% |
| Free Cash Flow Growth | 72.89% | -36.57% | -127.17% | 25.60% |
| Safety | ||||
| Net Debt / EBITDA | -0.36 | -0.30 | 0.26 | 0.17 |
| Interest Coverage | -1.72 | -28.28 | -16.60 | -1.82 |
| Efficiency | ||||
| Inventory Turnover | 11.35 | 1.46 | 3.57 | 5.06 |
| Cash Conversion Cycle | -107.71 | 183.12 | 151.44 | 130.59 |